82 related articles for article (PubMed ID: 24220933)
1. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
Cancer Chemother Pharmacol; 2014 Jan; 73(1):43-51. PubMed ID: 24220933
[TBL] [Abstract][Full Text] [Related]
2. Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
Cancer Chemother Pharmacol; 2014 Jan; 73(1):131-7. PubMed ID: 24326616
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
J Cancer Res Clin Oncol; 2014 Apr; 140(4):645-52. PubMed ID: 24562672
[TBL] [Abstract][Full Text] [Related]
4. Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
Histopathology; 2014 Feb; 64(3):412-20. PubMed ID: 24266856
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
[TBL] [Abstract][Full Text] [Related]
6. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
Vilmar AC; Santoni-Rugiu E; Sørensen JB
Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
[TBL] [Abstract][Full Text] [Related]
7. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
9. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
[TBL] [Abstract][Full Text] [Related]
10. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer.
Jakobsen JN; Sørensen JB
Cancer Chemother Pharmacol; 2012 Feb; 69(2):289-99. PubMed ID: 22130585
[TBL] [Abstract][Full Text] [Related]
11. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
12. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
[TBL] [Abstract][Full Text] [Related]
13. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
14. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.
Jakobsen JN; Santoni-Rugiu E; Ravn J; Sørensen JB
Eur J Cancer; 2013 Jul; 49(11):2494-503. PubMed ID: 23639410
[TBL] [Abstract][Full Text] [Related]
15. [The correlation between chemotherapeutic efficacy and breast cancer susceptibility gene 1 and class IIIβ-tubulin protein expression in non-small cell lung cancer patients].
Wan YY; Hui HX; Wang XW; Sun SA; Wu J
Zhonghua Nei Ke Za Zhi; 2011 Jun; 50(6):469-73. PubMed ID: 21781528
[TBL] [Abstract][Full Text] [Related]
16. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.
Levallet G; Bergot E; Antoine M; Creveuil C; Santos AO; Beau-Faller M; de Fraipont F; Brambilla E; Levallet J; Morin F; Westeel V; Wislez M; Quoix E; Debieuvre D; Dubois F; Rouquette I; Pujol JL; Moro-Sibilot D; Camonis J; Zalcman G;
Mol Cancer Ther; 2012 May; 11(5):1203-13. PubMed ID: 22411898
[TBL] [Abstract][Full Text] [Related]
17. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.
De Pas T; Pelosi G; de Braud F; Veronesi G; Curigliano G; Leon ME; Danesi R; Noberasco C; d'Aiuto M; Catalano G; Viale G; Spaggiari L
J Clin Oncol; 2004 Dec; 22(24):4966-70. PubMed ID: 15611511
[TBL] [Abstract][Full Text] [Related]
18. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
